The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.
대표청구항▼
1. A gel pharmaceutical composition obtained by combining the following ingredients which consist of: a) 1.3% to 1.7% (w/w) testosterone;b) 0.9% to 1.0% (w/w) isopropyl myristate;c) 67.0% to 74.0% (w/w) of a lower alcohol selected from the group consisting of methanol, ethanol, n-propanol, and isopr
1. A gel pharmaceutical composition obtained by combining the following ingredients which consist of: a) 1.3% to 1.7% (w/w) testosterone;b) 0.9% to 1.0% (w/w) isopropyl myristate;c) 67.0% to 74.0% (w/w) of a lower alcohol selected from the group consisting of methanol, ethanol, n-propanol, and isopropanol;d) 0.6% to 1.4% (w/w) of a gelling agent which is a polyacrylic acid;e) an amount of a neutralizer of the polyacrylic acid sufficient to form a gel; andf) water. 2. The gel pharmaceutical composition of claim 1, wherein the lower alcohol is ethanol. 3. The gel pharmaceutical composition of claim 2, wherein the ethanol is absolute ethanol. 4. The gel pharmaceutical composition of claim 2, wherein the ethanol is 95% (v/v) ethanol. 5. The gel pharmaceutical composition of claim 1, wherein the polyacrylic acid is a carbomer. 6. The gel pharmaceutical composition of claim 1, wherein the neutralizer is selected from the group consisting of: sodium hydroxide, ammonium hydroxide, potassium hydroxide, arginine, aminomethyl propanol, tetrahydroxypropyl ethylenediamine, triethanolamine, tromethamine, PEG-15 cocamine, diisopropanolamine and triisopropanolamine and combinations thereof. 7. The gel pharmaceutical composition of claim 6, wherein the neutralizer is sodium hydroxide. 8. The gel pharmaceutical composition of claim 1, wherein the testosterone in the gel pharmaceutical composition is in the range of 1.50% to 1.70% (w/w) testosterone. 9. The gel pharmaceutical composition of claim 1, obtained by combining the following ingredients which consist of: a) 1.3% to 1.7% (w/w) testosterone;b) 0.9% to 1.0% (w/w) isopropyl myristate;c) 67.0% to 74.0% (w/w) of absolute ethanol;d) 0.6% to 1.4% (w/w) of a polyacrylic acid;e) an amount of sodium hydroxide sufficient to form a gel; andf) water. 10. The gel pharmaceutical composition of claim 9, wherein the amount of sodium hydroxide is in the range of 1.0% to 10% (w/w) of 0.1 N sodium hydroxide. 11. The gel pharmaceutical composition of claim 1, wherein a therapeutically effective dose of the gel pharmaceutical composition for treatment of hypogonadism in a human male subject is 2.5 grams. 12. The gel pharmaceutical composition of claim 11, wherein the therapeutically effective dose comprises 40.5 milligrams of testosterone. 13. A gel pharmaceutical composition obtained by combining the following ingredients which consist of: a) 1.62% (w/w) testosterone;b) 1.0% (w/w) isopropyl myristate;c) 68.1% (w/w) absolute ethanol or 73.5% (w/w) of 95% (v/v) of ethanol;d) 1.0% (w/w) of a gelling agent which is a polyacrylic acid;e) an amount of a neutralizer of the polyacrylic acid sufficient to form a gel, wherein the neutralizer is selected from the group consisting of: sodium hydroxide, ammonium hydroxide, potassium hydroxide, arginine, aminomethyl propanol, tetrahydroxypropyl ethylenediamine, triethanolamine, tromethamine, PEG-15 cocamine, diisopropanolamine and triisopropanolamine and combinations thereof; andf) water. 14. The gel pharmaceutical composition of claim 13, wherein the polyacrylic acid is a carbomer. 15. The gel pharmaceutical composition of claim 13, wherein the neutralizer is sodium hydroxide. 16. The gel pharmaceutical composition of claim 13, obtained by combining the following ingredients which consist of: a) 1.62% (w/w) testosterone;b) 1.0% (w/w) isopropyl myristate;c) 68.1% (w/w) absolute ethanol or 73.5% (w/w) of 95% (v/v) ethanol;d) 1.0% (w/w) of a polyacrylic acid;e) an amount of sodium hydroxide sufficient to form a gel, wherein the amount of sodium hydroxide is in the range of 1.0% to 10% (w/w) of 0.1 N sodium hydroxide; andf) water. 17. The gel pharmaceutical composition of claim 16, wherein a therapeutically effective dose of the gel pharmaceutical composition for treatment of hypogonadism in a human male comprises 40.5 milligrams of testosterone. 18. The gel pharmaceutical composition of claim 16, wherein the amount of sodium hydroxide is about 7% of 0.1 N sodium hydroxide.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (223)
Atkinson Joseph G. (Montreal PA CAX) Baldwin John J. (Gwynedd Valley PA) McClure David E. (Lansdale PA), (3-Aralkylamino-2-or-propoxy)heterocyclic compounds.
Samour Carlos M. ; Krauser Scott F., Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering.
Place, Virgil A.; Wilson, Leland F.; Doherty, Jr., Paul C.; Hanamoto, Mark S.; Spivack, Alfred P.; Gesundheit, Neil; Bennett, Sean R., Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction.
Duffy John A. (West Milford NJ) Garrison Mark S. (White Plains NY) Menon Gopinathan K. (Wayne NJ) Scancarella Neil D. (Wyckoff NJ), Composition and method for reducing under-eye puffiness.
Hofman Petrus S. (Haarlem NLX) Hall David W. R. (Rotterdam NLX) Jaitly Kapil D. (Delft NLX), Compositions and method for inhibition of sebum synthesis.
Lu Mou-Ying F. (Lake Bluff IL) Reiland Thomas L. (Gages Lake IL), Compositions and method for the sublingual or buccal administration therapeutic agents.
Hale Ron L. (Woodside CA) Lu Amy (Los Altos CA) Solas Dennis (San Francisco CA) Selick Harold E. (Belmont CA) Oldenburg Kevin R. (Fremont CA) Zaffaroni Alejandro C. (Atherton CA), Compositions and methods for enhanced drug delivery.
Kanios David P. ; Gentile Joseph A. ; Mantelle Juan A. ; Sablotsky Steven, Compositions and methods for topical administration of pharmaceutically active agents.
Oettel Michael,DEX ; Golbs Siegfried,DEX ; Dittgen Michael,DEX ; Timpe Carsten,DEX ; Graser Thomas,DEX ; Hubler Doris,DEX, Compound preparation for the treatment of hypogonadal men and men with hypophyseal diseases.
Reed Barry Leonard,AUX ; Morgan Timothy Matthias,AUX ; Finnin Barrie Charles,AUX, Dermal penetration enhancers and drug delivery systems involving same.
El-Rashidy Ragab ; Heaton Jeremy P. W.,CAX ; Morales Alvaro,CAX ; Adams Michael A.,CAX, Dosage forms and method for ameliorating male erectile dysfunction.
Caldwell Larry J. (Lawrence KS) Gardner Colin R. (Lawrence KS) Cargill Robyn C. (Lawrence KS), Drug delivery device which can be retained in the stomach for a controlled period of time.
David B. Masters, Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices.
Lu Mou-Ying Fu (Lake Bluff IL) Subba Rao Gowdahallin N. (Mundelein IL) Lee Dennis Y. (Highland Park IL), Formulations and method of the percutaneous administration of leuprolide.
Elias Peter M. (Muir Beach CA) Feingold Kenneth R. (San Rafael CA) Thornfeldt Carl R. (Ontario OR), Lipids for epidermal moisturization and repair of barrier function.
Doherty ; Jr. Paul C. ; Place Virgil A. ; Smith William L., Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction.
Doherty ; Jr. Paul C. ; Place Virgil A. ; Smith William L., Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction.
Doherty ; Jr. Paul C. ; Place Virgil A. ; Smith William L., Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction.
Tang Reginald T. (Warren NJ) Mares Frank (Whippany NJ) Boyle ; Jr. William J. (Parsippany NJ) Chiu Tin-Ho (Millburn NJ) Patel Kundabhai M. (Landing NJ), Medical devices fabricated from homopolymers and copolymers having recurring carbonate units.
Ebert Charles D. (Salt Lake City UT) Patel Dinesh (Murray UT) Heiber Werner (Salt Lake City UT), Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective level.
Anderson ; Jr. Wesley R. (Gainesville FL) Bodor Nicholas S. (Gainesville FL) Simpkins James W. (Gainesville FL), Method for treating male sexual dysfunction.
Hussain Anwar A. ; Dittert Lewis W., Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction.
Aroonsakul Chaovanee (505 N. Lake Shore Dr. ; Ste. 3006 Chicago IL 60611), Method of treatment for central nervous system diseases such as Alzheimer\s disease and Parkinson\s disease.
Parab Prakash ; Yu Cheng Der Tony ; Patel Bhiku, Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage.
Spicer Darcy V. (Pasadena CA) Pike Malcolm C. (Long Beach CA), Methods and formulations for use in inhibiting conception and in treating benign gynecological disorders.
Ebert Charles D. (Salt Lake City UT) Patel Dinesh C. (Murray UT) Mazer Norman A. (Salt Lake City UT) Venkateshwaran Srinivasan (Salt Lake City UT), Methods for providing testosterone and optionally estrogen replacement therapy to women.
Raja G. Achari ; Shamim Ahmed ; Charanjit R. Behl ; Jorge C. deMeireles ; Tianquing Liu ; Vincent D. Romeo ; Anthony P. Sileno, Nasal delivery of apomorphine.
Garvey David S. ; de Tejada Inigo Saenz,ESX ; Earl Richard A. ; Khanapure Subhash P., Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use.
Patel Dinesh C. (Murray UT) Chang Yunik (Lakewood NJ), Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols.
Mauvais-Jarvis Pierre (12 ; Parc de Bearn F-92210 Saint Cloud FRX) Kuttenn Frdrique (6 ; Avenue des Gobelins F-75008 Paris FRX), Percutaneous administration of tamoxifen.
Linder Ernst (Mhlacker DEX) Maurer Helmut (Vaihingen DEX) Mller Klaus (Tamm DEX) Rieger Franz (Aalen DEX), Polarographic sensor and sensing system for determining oxygen content in gases.
Chen Tung-Fen ; Chiang Chia-Ming ; Jona Janan ; Joshi Priti ; Ramdas Asha, Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufactu.
Lee Eun Soo (Redwood City CA) Nedberge Diane E. (Los Altos CA) Yum Su Il (Los Altos CA), Skin permeation enhancer compositions using glycerol monolinoleate.
Chiang Chia-Ming (Foster City CA) Cleary Gary W. (San Mateo CA), Skin permeation enhancer compositions, and methods and transdermal systems associated therewith.
Miranda Jesus (Miami FL) Sablotsky Steven (Miami FL), Solubility parameter based drug delivery system and method for altering drug saturation concentration.
Moo-Young Alfred (Hastings-on-Hudson NY) Zepeda-Ortega Ana (Santiago CLX) Croxatto Horacio Bruno (Santiago CLX), Therapeutically effective topical application of ST1435.
Roentsch Elmer George (Stoddard NH) Snyder ; II William Scott (8526 E. Fort Cooper Rd. Inverness FL 34450), Topical formulation for local delivery of a pharmaceutically active agent.
Wick Steven M. (Mahtomedi MN) Schultz Helen J. (Falcon Heights MN) Nelson Gregory R. (Hudson WI) Mitra Amit K. (Woodbury MN) Berge Stephen M. (Shoreview MN), Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine.
Gale Robert M. (Los Altos CA) Enscore David J. (Sunnyvale CA) Nedberge Diane E. (Los Altos CA) Nelson Melinda (Sunnyvale CA) Cheng Yu-Ling (Cupertino CA) Libicki Shari B. (Palo Alto CA), Transdermal administration of progesterone, estradiol esters, and mixtures thereof.
Kim Kwon H. (Bridgewater NJ) Koplowitz Barry (Somerville NJ) Henderson Norman L. (Gladstone NJ), Transdermal antiandrogenic compositions and modulated process.
Grasela John C. ; Grasela Joseph E. ; Jubenville Robert M. ; McCloskey Joseph J., Transdermal delivery of medications using a combination of penetration enhancers.
Ebert Charles D. (Salt Lake City UT) Heiber Werner (Salt Lake City UT) Good William R. (Salt Lake City UT) Venkateshwaran Srinivasan (Salt Lake City UT), Transdermal delivery system with adhesive overlay and peel seal disc.
Nelson Gregory R. (St. Paul MN) Zerbe Horst-Georg (St. Paul MN) Moore Cheryl L. (St. Paul MN) Wick Steven M. (St. Paul MN), Transdermal estradiol delivery system.
Chien Yie W. (North Brunswick NJ) Chien Te-Yen (Piscataway NJ) Huang Yih-Chain (Piscataway NJ), Transdermal estrogen/progestin dosage unit, system and process.
Jona Janan ; Audett Jay ; Singh Noel, Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen.
Jona Janan ; Audett Jay ; Singh Noel, Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen.
Place Virgil A. ; Wilson Leland F. ; Doherty ; Jr. Paul C. ; Hanamoto Mark S. ; Spivack Alfred P. ; Gesundheit Neil ; Bennett Sean R., Treatment of female sexual dysfunction.
Place Virgil A. ; Wilson Leland F. ; Doherty ; Jr. Paul C. ; Hanamoto Mark S. ; Spivack Alfred P. ; Gesundheit Neil ; Bennett Sean R., Treatment of female sexual dysfunction.
Place Virgil A. ; Wilson Leland F. ; Doherty ; Jr. Paul C. ; Hanamoto Mark S. ; Spivack Alfred P. ; Gesundheit Neil ; Bennett Sean R., Treatment of female sexual dysfunction.
Virgil A. Place ; Leland F. Wilson ; Paul C. Doherty, Jr. ; Mark S. Hanamoto ; Alfred P. Spivack ; Neil Gesundheit ; Sean R. Bennett, Treatment of female sexual dysfunction using phosphodiesterase inhibitors.
Zoumas Barry L. ; Tarka Stanley M. ; McKim J. Michael ; Simmons Bryan J. ; Marks ; Jr. James G. ; Santanna Michael, Use of hydrolyzed cocoa butter for percutaneous absorption.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.